Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 10/20 | 0.68 |
| ▸ | SCN1A | P35498 | 7/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.68 |
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.68 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.68 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.68 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259345 | 0.94 | SCN3A (0.76) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3171480 | 0.93 | SCN3A (0.71) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3163178 | 0.92 | SCN3A (0.66) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3160783 | 0.90 | SCN3A (0.68) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3166390 | 0.89 | SCN3A (0.79) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3162733 | 0.89 | SCN3A (0.68) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3173728 | 0.88 | SCN3A (0.82) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3167725 | 0.87 | SCN3A (0.79) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3165494 | 0.86 | SCN3A (0.80) | SCN3ASCN1ASCN5ASCN8ASCN9A | |
| SCHEMBL3159571 | 0.86 | SCN3A (0.75) | SCN3ASCN1ASCN5ASCN8ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741934-B2 | Inhibitors of ion channels | PFIZER LIMITED (GB) | 2014-06-03 | — | — | US | disclosed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885SCN1A 6/4885SCN5A 15/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | SCN3A 13/4885SCN1A 6/4885SCN5A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.